Excellent new study out on SRB. Elizabeth Ryan who is doing the $1,000,000 Bill Gates study is one of several involved with it.
Found by research specialist bigbasslur who posts at Yahoo RIBT occasionally
http://www.mdpi.com/2072-6643/7/2/1282/htm
conclusion>>>
5. Conclusions
Previous research efforts characterizing SRB have largely focused on nutrient contents, phytochemicals (e.g., antioxidants) and the effects of consumption for the prevention and management of major chronic diseases. However, SRB modulation of the ~100 trillion microorganisms in the human gastrointestinal tract and alteration of their metabolic activities may result in the production of chemicals that confer its reported bioactivity. Despite the expected high level of inter-individual variation in the microbiota and metabolome, this pilot study demonstrated that SRB intake of 30 g/day changes stool bacterial populations after two and four weeks and results in the significant alteration of multiple plant- and microbe-derived stool metabolites. Additionally, several target outcome measures for larger clinical trials with SRB were identified. For example, SRB-associated increases in BCFA production that may reduce gut permeability and encourage the growth of Bifidobacterium should be confirmed. Other metabolites targeted for quantification in future studies include colonocyte-feeding SCFA, microbiota-modulating secondary bile acids, anti-inflammatory SRB phytochemicals and indole-2-carboxylic acid as a candidate SRB intake biomarker in stool. This research emphasizes the value of pilot trials in confirming the feasibility and acceptability of the SRB intervention and targeting appropriate outcome measures prior to conducting research in a larger cohort. Understanding which organisms create bioactive SRB metabolites will be critical to achieving gastrointestinal disease prevention outcomes in people. Considering the microbial metabolism of SRB in humans will also improve our ability to advance its utility for improved intestinal health and the prevention of major chronic diseases.
Found by research specialist bigbasslur who posts at Yahoo RIBT occasionally
http://www.mdpi.com/2072-6643/7/2/1282/htm
conclusion>>>
5. Conclusions
Previous research efforts characterizing SRB have largely focused on nutrient contents, phytochemicals (e.g., antioxidants) and the effects of consumption for the prevention and management of major chronic diseases. However, SRB modulation of the ~100 trillion microorganisms in the human gastrointestinal tract and alteration of their metabolic activities may result in the production of chemicals that confer its reported bioactivity. Despite the expected high level of inter-individual variation in the microbiota and metabolome, this pilot study demonstrated that SRB intake of 30 g/day changes stool bacterial populations after two and four weeks and results in the significant alteration of multiple plant- and microbe-derived stool metabolites. Additionally, several target outcome measures for larger clinical trials with SRB were identified. For example, SRB-associated increases in BCFA production that may reduce gut permeability and encourage the growth of Bifidobacterium should be confirmed. Other metabolites targeted for quantification in future studies include colonocyte-feeding SCFA, microbiota-modulating secondary bile acids, anti-inflammatory SRB phytochemicals and indole-2-carboxylic acid as a candidate SRB intake biomarker in stool. This research emphasizes the value of pilot trials in confirming the feasibility and acceptability of the SRB intervention and targeting appropriate outcome measures prior to conducting research in a larger cohort. Understanding which organisms create bioactive SRB metabolites will be critical to achieving gastrointestinal disease prevention outcomes in people. Considering the microbial metabolism of SRB in humans will also improve our ability to advance its utility for improved intestinal health and the prevention of major chronic diseases.
